Home > Boards > US OTC > Delisted > CardioVascular BioTherapeutics (fka CVBT)

<u>MAJOR NEWS: Venturis Therapeutics Insider Spills The Beans</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
walhall Member Profile
 
Followed By 0
Posts 335
Boards Moderated 1
Alias Born 09/15/16
160x600 placeholder
Corn Higher on Strong Spot Demand - Daily Grain Highlights
By Kirk Maltais
Front Month Nymex Natural Gas Fell 7.78% to Settle at $4.9890 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.01% to Settle at $2.4866 -- Data Talk
Housing Starts and Existing Home Sales on the Docket -- Data Week Ahead Update
Apple Launching HomePod Mini Speaker, New Line of AirPods
Top Company News of the Day
Grains Traders Look to USDA for Guidance; Sugar Trapped in Narrow Range
Adamis Pharma Shares Rise 16% After FDA Approves Zimhi for Opioid Overdose
Avadel Pharmaceuticals Shares Drop 14% After FDA Notification
STOXX Europe 50 Index Ends 0.58% Lower at 3607.17 -- Data Talk
EURO STOXX 50 Index Ends 0.75% Lower at 4151.40 -- Data Talk
STOXX Europe 600 Index Ends 0.50% Lower at 467.04 -- Data Talk
FTSE 100 Index Ends 0.42% Lower at 7203.83 -- Data Talk
DAX Ends 0.72% Lower at 15474.47 -- Data Talk
CAC 40 Index Ends 0.81% Lower at 6673.10 -- Data Talk
Dish Network Files FCC Complaint Against Tegna
FTSE Closed Down Due to Concerns Over Rising Energy Prices, and China's Low 3Q Numbers
Medtronic Plc Down Over 5%, On Pace for Largest Percent Decrease Since June 2020 -- Data Talk
Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
Interactive Brokers Launches Cryptocurrency Trading
Molecular Templates: Vertex Terminates Collaboration
Omeros Shares Tumble as FDA Turns Away Narsoplimab Application
U.S. Home-Builder Sentiment Rose in October on Strong Demand -NAHB
U.S. Industrial Production Fell in September as Supply-Chain Woes, Ida Hit Activity
Becton, Dickinson Unveils ESG Strategy for 2030
Avidity Biosciences Lead Program Gets FDA Fast-Track Designation
Maserati Postpones Launch of New SUV as Chip Shortages Bite
Southern Names Former NRC Chairman Svinicki to Board
VC Daily: Is This VC Cycle Virtuous or Vicious?
Italy Faces Capital Demand of More Than $8 Billion to Sell Monte Dei Paschi -Reuters
walhall   Saturday, 05/30/20 06:17:08 AM
Re: None
Post # of 3621 
MAJOR NEWS: Venturis Therapeutics Insider Spills The Beans

Someone I know who's also a Venturis Therapeutics / Cardiovascular Biotherapeutics (CVBT) shareholder had a phone conversation with an individual who used to work at Venturis Therapeutics, and found out what’s really going on. It's ugly (to no surprise).

Here are the highlights:

1) The individual indicated Venturis Therapeutics is broke and has no money, and has not had any money during his/her period of involvement. The lack of resources has led to departures of several executives. (Editorial comment - this explains the constant turnover in the leadership team, which I have noted in a series of posts over the last several years.)

2) This person said that not only is there no clinical trial activity going on, there is no plan for any clinical trial activity to happen. They have not even manufactured drug. This person said all the clinical programs are dead in the water.

3) The individual indicated the whole patent strategy is an effort to give the appearance of viability, and spending money on patents is cheap compared to clinical trials. This person does not believe that any of the new patents are actually meaningful. (Editorial comment - That’s obvious to anyone who has any background in science or medicine, or has any level of education.)

4) Grant Gordon has reportedly been in and out of hospitals due to his end-stage illness, and has been written off by insiders. (Editorial comment - That would partially explain why Venturis Therapeutics is flat broke—-in addition to insolvency, incompetent and uneducated leadership, etc.) If Grant Gordon has been the conduit for the funding for Venturis Therapeutics as has been reported from numerous sources, what does this mean for the future if he is out of time? Nothing good.

5) This individual believes the situation at Venturis Therapeutics is hopeless. It’s why he/she left. And he/she is still owed money that he/she believes he/she will never see.

Editorial comment – None of what this individual told my friend comes as a surprise. Still, it’s useful that it’s now been confirmed by someone who was in a position to know all.

Question – How many weeks will it be before Venturis Therapeutics shuts down/files for bankruptcy? I believe we are down to weeks at this point, not years.

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155716827


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences